Search Results
Your search for Matthew matches 8042 pages
Showing 2851 - 2900Integrated Palliative and Oncology Care for Patients Receiving Treatment for AML
In a study reported in JAMA Oncology, Areej El-Jawahri, MD, and colleagues found that integrated palliative and oncology care was associated with better quality of life vs usual care among patients receiving treatment for acute myeloid leukemia (AML). The investigators stated, “Patients with AML...
Patient-Reported Outcomes With Triplet Therapy for Newly Diagnosed Multiple Myeloma
In an analysis from the phase III MAIA trial reported in the Journal of Clinical Oncology, Perrot et al found that the combination of daratumumab, lenalidomide, and dexamethasone (D-Rd) was associated with better health-related quality-of-life outcomes vs lenalidomide and dexamethasone (Rd) in...
Ganglioside Vaccine Plus β-Glucan for Patients With High-Risk Neuroblastoma and Prior Disease Progression
In a single-institution phase II study reported in the Journal of Clinical Oncology, Cheung et al found that a subcutaneous ganglioside G2/G3 vaccine plus oral β-glucan produced antibody responses in patients with high-risk neuroblastoma, with higher anti–GD2-IgG1 titers being associated with...
Left Anterior Descending Coronary Artery Radiation Exposure, Cardiac Events, and Mortality in NSCLC
In a retrospective cohort analysis reported in JAMA Oncology, Atkins et al identified a volume (V, percent) of exposure of the left anterior descending (LAD) coronary artery to a radiation dose (V15 Gy ≥10%) that is an independent risk factor for major adverse cardiac events and all-cause mortality ...
Neoadjuvant Chemotherapy and Overall Survival in Metastatic Endometrial Cancer
In a National Cancer Database analysis reported in JAMA Network Open, Tobias et al found that receipt of neoadjuvant chemotherapy was associated with improved short-term but not long-term survival vs primary debulking surgery in patients with metastatic endometrial cancer. As stated by the...
Addition of First-Line Pembrolizumab to Chemotherapy in Metastatic Triple-Negative Breast Cancer: KEYNOTE-355
As reported in The Lancet by Javier Cortes, MD, and colleagues, the phase III KEYNOTE-355 trial has shown that the addition of pembrolizumab to chemotherapy improved progression-free survival among previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast...
Gemogenovatucel-T Maintenance in Stage III/IV Ovarian Cancer
In the phase IIb VITAL trial reported in The Lancet Oncology, Rocconi et al found that front-line maintenance with the autologous tumor cell vaccine gemogenovatucel-T did not improve recurrence-free survival vs placebo in patients with stage III/IV ovarian cancer in clinical complete response after ...
Risk of COVID-19 Infection in Patients With Cancer: Effect of Time of Diagnosis and Race
In a study reported in JAMA Oncology, Wang et al found that patients with cancer were at a greater risk of being infected with COVID-19 and having worse outcomes vs patients without cancer. Risk was greatest among patients with a more recent diagnosis and was even further exacerbated among Black...
Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease
In an observational cohort study reported in JAMA Oncology, Catherine H. Van Poznak, MD, FASCO, and colleagues found that the 3-year incidence of osteonecrosis of the jaw was 2.8% among patients with cancer receiving zoledronic acid for metastatic bone disease. Shorter dosing interval, fewer teeth, ...
Intensity of Active Surveillance in Patients With Rectal Cancer Managed With a Watch-and-Wait Approach
In a study reported in The Lancet Oncology, Fernandez et al found high rates of conditional recurrence-free survival during watch-and-wait surveillance among patients with rectal cancer who maintained clinical complete response to neoadjuvant chemotherapy for 1, 3, or 5 years. Study Details In the...
Pembrolizumab Plus Chemotherapy for Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer
On November 13, 2020, pembrolizumab (Keytruda) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for use in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer with tumors expressing PD-L1 (Combined ...
Addition of Capivasertib to Docetaxel/Prednisolone in Patients With Metastatic Castration-Resistant Prostate Cancer
In the phase II ProCAID study reported in the Journal of Clinical Oncology, Crabb et al found that the addition of the pan-AKT inhibitor capivasertib to docetaxel and prednisolone did not significantly improve progression-free survival in patients with metastatic castration-resistant prostate...
Pembrolizumab Improves Progression-Free Survival vs Chemotherapy in First-Line Treatment of Microsatellite Instability–High Advanced Colorectal Cancer
As reported in The New England Journal of Medicine by Thierry André, MD, of Sorbonne Université and Hôpital Saint Antoine, Paris, and colleagues, the second interim analysis of the phase III KEYNOTE-177 trial has shown significantly prolonged progression-free survival with pembrolizumab vs...
Pralsetinib for RET-Altered Thyroid Cancers
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 1, 2020, pralsetinib (Gavreto) was granted...
Germline-Somatic Interactions in Advanced Urothelial Cancer and Their Role in Disease Progression
In a study reported in Nature Communications, Bishoy M. Faltas, MD, of the Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, and colleagues identified common germline-somatic variant interactions in advanced urothelial cancer, with these...
Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow
On November 25, 2020, naxitamab-gqgk (Danyelza) was granted accelerated approval for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone...
Radiotherapy and Chemotherapy Before Total Mesorectal Excision for Locally Advanced Rectal Cancer: Comparison of Regimens
As reported in The Lancet Oncology by Bahadoer et al, the phase III RAPIDO trial has shown improved 3-year disease-related treatment failure with preoperative short-course radiotherapy followed by chemotherapy and total mesorectal excision (TME) vs preoperative chemoradiotherapy, TME, and optional...
Association of Out-of-Pocket Costs for Tyrosine Kinase Inhibitors With Outcomes in Patients With EGFR- and ALK-Positive Advanced NSCLC
In a single-institution study reported in JCO Oncology Practice, Bernardo H.L. Goulart, MD, and colleagues found that higher out-of-pocket costs for tyrosine kinase inhibitors (TKIs) were associated with reduced adherence to and increased discontinuation of TKI therapy—as well as poorer overall...
Does Melflufen Plus Dexamethasone Show Activity in Heavily Pretreated Patients With Relapsed and Refractory Multiple Myeloma?
In the phase II HORIZON study reported in the Journal of Clinical Oncology, Paul G. Richardson, MD, and colleagues found that the combination of the peptide-drug conjugate melflufen and dexamethasone showed activity in patients with heavily pretreated relapsed and refractory multiple myeloma....
Pembrolizumab in Combination With a Therapeutic DNA Vaccine for HPV-Positive Advanced Cervical Cancer
As reported in The Lancet Oncology by Youn et al, interim results of a Korean phase II trial indicated activity with the combination of pembrolizumab plus the therapeutic DNA vaccine GX-188E in patients with human papillomavirus (HPV)-16– or HPV-18–positive advanced cervical cancer. GX-188E...
Updated Results of CASPIAN Trial: Addition of Durvalumab With or Without Tremelimumab to Chemotherapy in Extensive-Stage SCLC
As reported in The Lancet Oncology by Goldman et al, updated results from the phase III CASPIAN trial showed maintained improvement in overall survival with first-line durvalumab plus platinum/etoposide vs platinum/etoposide in patients with extensive-stage small cell lung cancer (SCLC). However,...
Addition of Chemotherapy to Local Therapy in Women Aged 70 or Older With Triple-Negative Breast Cancer
In a National Cancer Database analysis reported in The Lancet Oncology, Crozier et al found that receipt of neoadjuvant or adjuvant chemotherapy was associated with improved overall survival among women aged 70 or older undergoing surgery for stage I to III triple-negative breast cancer. Study...
Changes in Care and Well-Being Among Patients With Cancer During Initial Stage of the COVID-19 Pandemic
In a Dutch study reported in JAMA Oncology, van de Poll-Franse et al found that a substantial proportion of patients with cancer had changes in care within 4 to 6 weeks after the first announcement of a COVID-19–related lockdown. Patients with cancer surveyed reported levels of quality of life,...
Spectrum of Germline-Somatic Interactions in Advanced Urothelial Cancer
In a study reported in Nature Communications, Vosoughi et al identified common germline-somatic variant interactions in advanced urothelial cancer, with these interactions appearing to play a central role in disease progression. As stated by the investigators, “The prevalence and the biologic...
Radiation Facility Volume and Overall Survival in Patients With Node-Positive Prostate Cancer Treated With External-Beam Radiation Therapy and Androgen-Deprivation Therapy
In a National Cancer Database analysis reported in JAMA Network Open, Patel et al found that treatment at facilities with high vs low radiation case volumes was associated with improved overall survival in men with node-positive prostate cancer receiving curative-intent external-beam radiation...
Oral Panobinostat and Dexamethasone Plus Subcutaneous Bortezomib for Patients With Relapsed or Refractory Multiple Myeloma
The randomized phase II PANORAMA 3 trial found that when used in combination with subcutaneous bortezomib and oral dexamethasone, oral panobinostat produced higher response rates with 20-mg dosing regimens and lower toxicity with a 10-mg regimen. The safety profile also appeared to be better than...
Initiative to Increase Referrals of Patients With Gastrointestinal Cancer to a Specialized Rehabilitation Program
In a single-institution study reported in JCO Oncology Practice, Nadler et al describe the development of an intervention at Princess Margaret Cancer Centre, Toronto, that succeeded in increasing referrals of patients with gastrointestinal cancer to a cancer rehabilitation program. As stated by the ...
Meta-analysis of Radiotherapy With Adjuvant vs Neoadjuvant Androgen-Deprivation Therapy for Localized Prostate Cancer
In an individual patient meta-analysis reported in the Journal of Clinical Oncology, Daniel E. Spratt, MD, and colleagues found that adjuvant androgen-deprivation therapy (ADT) was associated with improved progression free-survival vs neoadjuvant ADT in patients receiving radiotherapy for localized ...
Pembrolizumab vs Chemotherapy in First-Line Treatment of Microsatellite Instability–High Advanced Colorectal Cancer: KEYNOTE-177 Trial
As reported in The New England Journal of Medicine, the second interim analysis of the phase III KEYNOTE-177 trial has shown significantly prolonged progression-free survival with pembrolizumab vs fluorouracil (5-FU)-based chemotherapy as first-line treatment of patients with advanced...
Cost-Effectiveness of Neoadjuvant/Adjuvant Treatment Strategies for HER2-Positive Breast Cancer
In a study reported in JAMA Network Open, Kunst et al compared five neoadjuvant-adjuvant treatment strategies for patients with HER2-positive breast cancer and identified one that was associated with both improved outcomes and cost savings. The researchers found that a strategy of neoadjuvant...
Meta-analysis of Toxicity and Treatment Outcomes With Stereotactic Ablative Radiotherapy for Oligometastatic Cancer
In a systematic review and meta-analysis reported in JAMA Oncology, Lehrer et al found that stereotactic ablative radiotherapy (SABR) for oligometastatic cancer was associated with “clinically acceptable” rates of severe acute and late toxicities as well as 1-year disease outcomes. As stated by the ...
SABCS 2020: New Prognostic Tool to Determine Individual Risk of Distant Recurrence, Benefit of Adjuvant Chemotherapy in Early Breast Cancer
In a study presented at the 2020 San Antonio Breast Cancer Symposium (Abstract GS4-10) and concurrently published in the Journal of Clinical Oncology, Joseph A. Sparano, MD, and colleagues described the development and validation of a new prognostic tool. RSClin integrates the 21-gene recurrence...
Potential Impact of State Government Crisis Standards-of-Care Guidelines on Resource Allocation for Patients With Cancer
In a study reported in JAMA Oncology, Hantel et al found that among U.S. states with crisis standards-of-care guidelines, 55% deprioritized some patients with cancer in resource allocation and 26% included cancer-related categorical exclusions. As stated by the investigators, “State crisis...
Meta-analysis of Outcomes With Systemic Therapy in First- and Second-Line Treatments of Advanced HCC
In a systematic review and network meta-analysis reported in JAMA Oncology, Mohamad Bassam Sonbol, MD, of Mayo Clinic Cancer Center, Phoenix, and colleagues, found that atezolizumab plus bevacizumab outperformed other regimens in the first-line treatment of advanced hepatocellular carcinoma (HCC)...
Continued Progression-Free and Overall Survival Superiority of First-Line Pembrolizumab/Axitinib vs Sunitinib
As reported in The Lancet Oncology by Thomas Powles, MD, of Barts Cancer Institute, London, and colleagues, extended follow-up of the phase III KEYNOTE-426 trial shows continued progression-free and overall survival superiority with pembrolizumab/axitinib vs sunitinib alone in first-line treatment ...
Improved Outcomes With Neoadjuvant Paclitaxel Plus Trastuzumab/Lapatinib vs Paclitaxel/Trastuzumab in HER2-Positive Breast Cancer
In a 7-year follow-up of the phase III CALGB 40601/Alliance trial reported in the Journal of Clinical Oncology, Aranzazu Fernandez-Martinez, MD, of Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, and colleagues found that neoadjuvant paclitaxel combined with a dual...
No Reduced Recurrence Risk With Perioperative Aromatase Inhibitor Use in HR-Positive Breast Cancer
In the UK phase III POETIC trial reported in The Lancet Oncology, Ian Smith, MD, of The Royal Marsden NHS Foundation Trust, London, and colleagues, found that perioperative aromatase inhibitor therapy did not reduce the risk of recurrence in postmenopausal women with hormone receptor (HR)-positive...
Meta-analysis Shows Superior Disease-Free and Overall Survival With Measurable Residual Disease Negativity in AML
In a systematic review and meta-analysis reported in JAMA Oncology, Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, and colleagues, found that measurable residual disease (MRD) negativity is associated with superior disease-free and overall survival in patients with...
How Did the COVID-19 Pandemic Affect Initiation of Cancer Treatment in England?
In a retrospective analysis reported in The Lancet Oncology, Clark et al found that new prescriptions for systemic anticancer treatment in England initially declined significantly after societal lockdown in response to the COVID-19 pandemic. However, they then increased to higher than prepandemic...
Interference of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-Free DNA Testing
In a study reported in JAMA Oncology, Jensen and colleagues found that clonal hematopoiesis of indeterminate potential (CHIP) involving DNA repair genes can interfere with prostate cancer plasma cell-free DNA testing used to determine eligibility for poly (ADP-ribose) polymerase (PARP) inhibitor...
Matthew S. Davids, MD, on CLL/SLL: New Data on Ibrutinib, Venetoclax, and Rituximab Therapies
Matthew S. Davids, MD, of Dana-Farber Cancer Institute, summarizes three key studies from a session he co-moderated on ibrutinib plus venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), long-term responses to these agents for ...
Proportion of Never-Smokers Among Patients With Lung Cancer in Seven U.S. States
In a study reported in a research letter in JAMA Oncology, Siegel et al found that never-smokers accounted for 12.5% of patients diagnosed with lung cancer in seven U.S. states during a recent 6-year period, with women accounting for a higher proportion than men. Study Details The study included...
Circulating Tumor DNA and Disease-Free Survival in Patients With Breast Cancer
In a systematic review and meta-analysis reported in JAMA Network Open, Cullinane et al found that higher levels of plasma circulating tumor DNA (ctDNA) were associated with poorer disease-free survival in patients with both early and advanced breast cancer, with the association being stronger with ...
The COVID-19 Pandemic and Cancer Care for Older Patients in the United States: Effect on Diagnosis and Treatment
In a study of data from a Medicare fee-for-service population reported in JCO Clinical Cancer Informatics, Debra Patt, MD, PhD, MBA, and colleagues found that the COVID-19 pandemic has resulted in a “substantial decrease in cancer screenings, visits, therapy, and surgeries among older patients with ...
Analysis of Adjuvant Therapies for Early-Stage Triple-Negative Breast Cancer
In a population-based cohort study reported in JAMA Network Open, Zhai et al found that adjuvant therapies were associated with improved overall survival among patients with stage I (T1 N0 M0) triple-negative breast cancer, with adjuvant chemotherapy being associated with improved breast...
Native American Ancestry May Impact Somatic Alterations Among Latin American Patients With Lung Cancer
A research brief by Carrot-Zhang et al published in Cancer Discovery investigating inherited lung cancer risk—especially in nonsmokers—in Latin America has found that independent of smoking status, variation in EGFR and KRAS mutation frequency in Latin American patients with lung cancer was...
Association of Fall and Fracture Risk With Androgen Receptor Inhibitor Therapy for Prostate Cancer
In a systematic review and meta-analysis reported in JAMA Network Open, Myint et al found that androgen receptor inhibitor therapy for prostate cancer was associated with an increased risk of both falls and fractures. Study Details The meta-analysis included 11 randomized trials reported through...
Study Explores Duration of Shedding of Viable SARS-CoV-2 in Patients With Cancer After Immunosuppressive Therapy
In a single-institution study reported in a letter to the editor in The New England Journal of Medicine, Aydillo et al found that SARS-CoV-2 RNA could be detected in patients with COVID-19 receiving immunosuppressive treatment for cancer for as long as 78 days after the onset of virus symptoms. The ...
Definitive SBRT and Outcomes in Adult Patients With Extracranial Oligometastasis
In a retrospective case series reported in JAMA Network Open, Poon et al found that definitive stereotactic body radiotherapy (SBRT) was associated with good long-term overall survival and delayed widespread disease progression—but “modest” progression-free survival—in adults with extracranial...
End-of-Life Care Among Commercially Insured Women Younger Than 65 With Metastatic Breast Cancer
In a study reported in JCO Oncology Practice, Ferrario et al found a sizable increase in end-of-life intensive care unit (ICU) admissions and a small but significant increase in emergency department visits over time among commercially insured women younger than age 65 with metastatic breast cancer...
